QUARTERLY REPORT JANUARY - MARCH 2005
• Clinical trial application for KB2115 submitted to the Swedish Medical Products Agency • Per Olof Wallström appointed as new President for Karo Bio • Significant milestone payment from Merck & Co for initiation of phase I clinical trials received • On April 11, Karo Bio announced that Merck had decided to discontinue development of the lead compound in clinical trials. A back-up compound is being studied in preclinical testing • New potent compounds for treatment of dyslipidemia discovered • Continued good progress in the Wyeth Pharmaceuticals collaboration • Net sales amounted to MSEK 44.5